Search Results | Diabetes Care | American Diabetes Association

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Haptoglobin Phenotype Modifies the Effect of Fenofibrate on Risk of Coronary Event: ACCORD Lipid Trial

Rachel A. Warren, Allie S. Carew, Pantelis Andreou, Christine Herman, Andrew P. Levy, Henry N. Ginsberg, John Sapp, Eric B. Rimm, Susan Kirkland, Leah E. Cahill

Diabetes Care 2022;45(1):241–250

DOI: https://doi.org/10.2337/dc21-1429

Published: 16 November 2021

View article

Journal Articles

Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study

The Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Study Group

Diabetes Care 2016;39(7):1089–1100

DOI: https://doi.org/10.2337/dc16-0024

Published: 11 June 2016

View article

Includes: Supplementary data

Journal Articles

Effect of Combination Therapy With Fenofibrate and Simvastatin on Postprandial Lipemia in the ACCORD Lipid Trial

Gissette Reyes-Soffer, MD, Colleen I. Ngai, BS, Laura Lovato, MS, Wahida Karmally, DRPH, Rajasekhar Ramakrishnan, SCD, Stephen Holleran, BS, Henry N. Ginsberg, MD

Diabetes Care 2013;36(2):422–428

DOI: https://doi.org/10.2337/dc11-2556

Published: 17 January 2013

View article

Journal Articles

Effect of Extended-Release Niacin on New-Onset Diabetes Among Hyperlipidemic Patients Treated With Ezetimibe/Simvastatin in a Randomized Controlled Trial

John R. Guyton, MD, Sergio Fazio, MD, Adeniyi J. Adewale, PHD, Erin Jensen, MS, Joanne E. Tomassini, PHD, Arvind Shah, PHD, Andrew M. Tershakovec, MD

Diabetes Care 2012;35(4):857–860

DOI: https://doi.org/10.2337/dc11-1369

Published: 13 March 2012

View article

Includes: Supplementary data

Journal Articles

Simvastatin Improves Flow-Mediated Dilation but Reduces Adiponectin Levels and Insulin Sensitivity in Hypercholesterolemic Patients

Kwang Kon Koh, MD, Michael J. Quon, MD, PHD, Seung Hwan Han, MD, Yonghee Lee, PHD, Jeong Yeal Ahn, MD, Soo Jin Kim, RN, Yesl Koh, BS, Eak Kyun Shin, MD

Diabetes Care 2008;31(4):776–782

DOI: https://doi.org/10.2337/dc07-2199

Published: 01 April 2008

View article

Journal Articles

Simvastatin Reduces Plasma Osteoprotegerin in Type 2 Diabetic Patients With Microalbuminuria

Birgitte Nellemann, RF, Lars C. Gormsen, MD, Jens Dollerup, MSC, Ole Schmitz, MD, Carl E. Mogensen, MD, Lars M. Rasmussen, MD, Søren Nielsen, MD

Diabetes Care 2007;30(12):3122–3124

DOI: https://doi.org/10.2337/dc07-0919

Published: 01 December 2007

View article

Journal Articles

The Effect of Statin Therapy on Endothelial Function in Type 2 Diabetes Without Manifest Cardiovascular Disease

Edith D. Beishuizen, MD, Jouke T. Tamsma, MD, PHD, J. Wouter Jukema, MD, PHD, Marcel A. van de Ree, MD, PHD, J. Carel M. van der Vijver, MD, PHD, A. Edo Meinders, MD, PHD, Menno V. Huisman, MD, PHD

Diabetes Care 2005;28(7):1668–1674

DOI: https://doi.org/10.2337/diacare.28.7.1668

Published: 01 July 2005

View article

Journal Articles

Simvastatin, Fenofibrate, and Rhabdomyolysis

Sindhu S. Jacob, MD, Sony Jacob, MD, Craig Williams, PHARMD, Mark A. Deeg, MD, PHD

Diabetes Care 2005;28(5):1258

DOI: https://doi.org/10.2337/diacare.28.5.1258

Published: 01 May 2005

View article

Journal Articles

Two-Year Statin Therapy Does Not Alter the Progression of Intima-Media Thickness in Patients With Type 2 Diabetes Without Manifest Cardiovascular Disease

Edith D. Beishuizen, MD, Marcel A. van de Ree, MD, PHD, J. Wouter Jukema, MD, PHD, Jouke T. Tamsma, MD, PHD, J. Carel M. van der Vijver, MD, PHD, A. Edo Meinders, MD, PHD, Hein Putter, PHD, Menno V. Huisman, MD, PHD

Diabetes Care 2004;27(12):2887–2892

DOI: https://doi.org/10.2337/diacare.27.12.2887

Published: 01 December 2004

View article

Journal Articles

Role of Simvastatin as an Immunomodulator in Type 2 Diabetes: Response to Lopes-Virella et al.

Michelle Petrou, BSC, Marialena Gregoriades, MB, CHB, Vassilios Vassiliou, MB, BS

Diabetes Care 2004;27(8):2093–2094

DOI: https://doi.org/10.2337/diacare.27.8.2093-a

Published: 01 August 2004

View article

Journal Articles

Reduction of Cardiovascular Events by Simvastatin in Nondiabetic Coronary Heart Disease Patients With and Without the Metabolic Syndrome: Subgroup analyses of the Scandinavian Simvastatin Survival Study (4S)

Kalevi Pyörälä, MD, Christie M. Ballantyne, MD, Barry Gumbiner, MD, Michael W. Lee, PHD, Arvind Shah, PHD, Michael J. Davies, PHD, Yale B. Mitchel, MD, Terje R. Pedersen, MD, John Kjekshus, MD, for the Scandinavian Simvastatin Survival Study Group

Diabetes Care 2004;27(7):1735–1740

DOI: https://doi.org/10.2337/diacare.27.7.1735

Published: 01 July 2004

View article

Journal Articles

Role of Simvastatin as an Immunomodulator in Type 2 Diabetes

Maria F. Lopes-Virella, MD, PHD, Marina Mironova, MD, PHD, Elias Stephan, MD, Ramon Durazo-Arvizu, PHD, Gabriel Virella, MD, PHD

Diabetes Care 2004;27(4):908–913

DOI: https://doi.org/10.2337/diacare.27.4.908

Published: 01 April 2004

View article

Journal Articles

Validation of the Archimedes Diabetes Model

David M. Eddy, MD, PHD, Leonard Schlessinger, PHD

Diabetes Care 2003;26(11):3102–3110

DOI: https://doi.org/10.2337/diacare.26.11.3102

Published: 01 November 2003

View article

Journal Articles

New Strategies for the Treatment of Diabetic Dyslipidemia

Steven M. Haffner, MD, Ronald B. Goldberg, MD

Diabetes Care 2002;25(7):1237–1239

DOI: https://doi.org/10.2337/diacare.25.7.1237

Published: 01 July 2002

View article

Journal Articles

Response to Egede

Steven A. Grover, MD, Louis Coupal, MSC, Hanna Zowall, MSC

Diabetes Care 2001;24(7):1306–1307

DOI: https://doi.org/10.2337/diacare.24.7.1306-a

Published: 01 July 2001

View article

Journal Articles

How Cost-Effective Is the Treatment of Dyslipidemia in Patients With Diabetes but Without Cardiovascular Disease?

Steven A. Grover, MD, MPA, FRCPC, Louis Coupal, MSC, Hanna Zowall, MSC, Charles M. Alexander, MD, FACP, FACE, Thomas W. Weiss, DRPH, Daniel R.J. Gomes, MSC

Diabetes Care 2001;24(1):45–50

DOI: https://doi.org/10.2337/diacare.24.1.45

Published: 01 January 2001

View article

Meeting Abstracts

A drug interaction between troglitazone and simvastatin.

J C Lin, M K Ito

Diabetes Care 1999;22(12):2104–2106

DOI: https://doi.org/10.2337/diacare.22.12.2104a

Published: 01 December 1999

View article

Meeting Abstracts

Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study.

W H Herman, C M Alexander, J R Cook, S J Boccuzzi, T A Musliner, T R Pedersen, J Kjekshus, K Pyörälä

Diabetes Care 1999;22(11):1771–1778

DOI: https://doi.org/10.2337/diacare.22.11.1771

Published: 01 November 1999

View article

Meeting Abstracts

Endothelial dysfunction is not reversed by simvastatin treatment in type 2 diabetic patients with hypercholesterolemia.

W H Sheu, B L Juang, Y T Chen, W J Lee

Diabetes Care 1999;22(7):1224–1225

DOI: https://doi.org/10.2337/diacare.22.7.1224

Published: 01 July 1999

View article

Journal Articles

Treatment of Hypercholesterolemia and Combined Hyperlipidemia With Simvastatin and Gemfibrozil in Patients With NIPPM: A multicenter comparison study

Matti J Tikkanen, MD, Markku Laakso, MD, Marja Ilmonen, MD, Eero Helve, MD, Esko Kaarsalo, MD, Esa Kilkki, MD, Juha Saltevo, MD, The Study Group

Diabetes Care 1998;21(4):477–481

DOI: https://doi.org/10.2337/diacare.21.4.477

Published: 01 April 1998

View article

NARROW

Haptoglobin Phenotype Modifies the Effect of Fenofibrate on Risk of Coronary Event: ACCORD Lipid Trial

Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study

Effect of Combination Therapy With Fenofibrate and Simvastatin on Postprandial Lipemia in the ACCORD Lipid Trial

Effect of Extended-Release Niacin on New-Onset Diabetes Among Hyperlipidemic Patients Treated With Ezetimibe/Simvastatin in a Randomized Controlled Trial

Simvastatin Improves Flow-Mediated Dilation but Reduces Adiponectin Levels and Insulin Sensitivity in Hypercholesterolemic Patients

Simvastatin Reduces Plasma Osteoprotegerin in Type 2 Diabetic Patients With Microalbuminuria

The Effect of Statin Therapy on Endothelial Function in Type 2 Diabetes Without Manifest Cardiovascular Disease

Simvastatin, Fenofibrate, and Rhabdomyolysis

Two-Year Statin Therapy Does Not Alter the Progression of Intima-Media Thickness in Patients With Type 2 Diabetes Without Manifest Cardiovascular Disease

Role of Simvastatin as an Immunomodulator in Type 2 Diabetes: Response to Lopes-Virella et al.

Reduction of Cardiovascular Events by Simvastatin in Nondiabetic Coronary Heart Disease Patients With and Without the Metabolic Syndrome: Subgroup analyses of the Scandinavian Simvastatin Survival Study (4S)

Role of Simvastatin as an Immunomodulator in Type 2 Diabetes

Validation of the Archimedes Diabetes Model

New Strategies for the Treatment of Diabetic Dyslipidemia

Response to Egede

How Cost-Effective Is the Treatment of Dyslipidemia in Patients With Diabetes but Without Cardiovascular Disease?

A drug interaction between troglitazone and simvastatin.

Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study.

Endothelial dysfunction is not reversed by simvastatin treatment in type 2 diabetic patients with hypercholesterolemia.

Treatment of Hypercholesterolemia and Combined Hyperlipidemia With Simvastatin and Gemfibrozil in Patients With NIPPM: A multicenter comparison study

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Other

About

Resources

This Feature Is Available To Subscribers Only